Active Ingredient History
Brimonidine reduces the amount of fluid in the eye, which decreases pressure inside the eye. Brimonidine ophthalmic (for the eyes) is used to treat open-angle glaucoma or ocular hypertension (high pressure inside the eye). Brimonidine is an alpha adrenergic receptor agonist (primarily alpha-2). Fluorophotometric studies in animals and humans suggest that Brimonidine has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow. Adverse reactions occurring in approximately 1020% of the subjects receiving brimonidine ophthalmic solution (0.1-0.2%) included: allergic conjunctivitis, conjunctival hyperemia, and eye pruritus. Because Brimonidine may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with Brimonidine is advised. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Alcohol-Related Disorders (Early Phase 1)
Blepharoptosis (Phase 4)
Brimonidine Tartrate (Phase 3)
Capillaries (Phase 3)
Conjunctivitis, Allergic (Phase 2)
Corneal Diseases (Phase 3)
Corneal Edema (Phase 3)
Deficiency Diseases (Early Phase 1)
Diabetic Retinopathy (Phase 2/Phase 3)
Dry Eye Syndromes (Phase 3)
Erythema (Phase 4)
Eye Diseases (Phase 1)
Eye Diseases, Hereditary (Phase 4)
Flushing (Early Phase 1)
General Surgery (Phase 2)
Geographic Atrophy (Phase 2)
Glaucoma ()
Glaucoma, Angle-Closure (Phase 4)
Graft vs Host Disease (Phase 3)
Hand-Foot Syndrome (Phase 2)
Healthy Volunteers (Phase 2)
Hyperemia (Phase 3)
Hypertension (Phase 4)
Intraocular Pressure (Phase 4)
Low Tension Glaucoma (Phase 4)
Lubricant Eye Drops (Phase 3)
Macular Degeneration (Phase 2)
Macular Edema (Phase 2)
Meibomian Gland Dysfunction (Phase 1/Phase 2)
Multiple Sclerosis (Phase 4)
Ocular Physiological Phenomena (Phase 4)
Ophthalmic Solutions (Phase 3)
Posterior Capsule of the Lens (Phase 4)
Presbyopia (Phase 3)
Prostatic Neoplasms (Phase 4)
Pseudophakia (Early Phase 1)
Regional Blood Flow (Phase 4)
Retinal Diseases (Phase 2)
Retinitis Pigmentosa (Phase 1/Phase 2)
Rosacea ()
Telangiectasis (Phase 4)
Vision, Ocular (Phase 2)
Visual Acuity (Phase 3)
Vitrectomy (Phase 1)
Vitreous Body (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
